medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

1
Risk and protective factors of SARS-CoV-2 infection – Meta-regression of data from
worldwide nations

Hisato Takagi, MD, PhD, Toshiki Kuno, MD, PhD, Yujiro Yokoyama, MD, Hiroki
Ueyama, MD, Takuya Matsushiro, MD, Yosuke Hari, MD, Tomo Ando, MD

Author Affiliations: Shizuoka Medical Center, Shizuoka, Japan; Kitasato University
School of Medicine, Sagamihara, Japan (HT, TM, YH); Mount Sinai Beth Israel Medical
Center, New York, NY (TK, HU); Easton Hospital, Easton, PA (YY), and New York
Presbyterian Hospital/Columbia University Medical Center, New York, NY (TA).

Corresponding Authors: Hisato Takagi, MD, PhD, Department of Cardiovascular
Surgery, Shizuoka Medical Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka
411-8611, Japan (kfgth973@ybb.ne.jp).

Author Contributions: HT had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: HT; Acquisition, analysis, or interpretation of data: HT, TK, YH,
TA; Drafting of the manuscript: HT; Critical revision of the manuscript for important
intellectual content: TK, YH, TA; Statistical analysis: HT, TK, TA; Administrative,
technical, or material support: YY, HU, TM; Supervision: TA.

Conflict of Interest Disclosures: None reported.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

2
Abstract
Although it has been reported that coexistent chronic diseases are strongly associated with
COVID-19 severity, investigations of predictors for SARS-CoV-2 infection itself have
been seldom performed.

To screen potential risk and protective factors for SARS-CoV-

2 infection, meta-regression of data from worldwide nations were herein conducted.

We

extracted total confirmed COVID-19 cases in worldwide 180 nations (May 31, 2020),
nation total population, population ages 0-14/≥65, GDP/GNI per capita, PPP, life
expectancy at birth, medical-doctor and nursing/midwifery-personnel density,
hypertension/obesity/diabetes prevalence, annual PM2.5 concentrations, daily ultraviolet
radiation, population using safely-managed drinking-water/sanitation services and handwashing facility with soap/water, inbound tourism, and bachelor’s or equivalent (ISCED
6).

Restricted maximum-likelihood meta-regression in the random-effects model was

performed using Comprehensive Meta-Analysis version 3.

To adjust for other

covariates, we conducted the hierarchical multivariate models.

A slope (coefficient) of

the meta-regression line for the COVID-19 prevalence was significantly negative for
population ages 0-14 (–0.0636; P = .0021) and positive for obesity prevalence (0.0411;
P = .0099) and annual PM2.5 concentrations in urban areas (0.0158; P = .0454), which
would indicate that the COVID-19 prevalence decreases significantly as children increase
and that the COVID-19 prevalence increases significantly as the obese and PM2.5
increase.

In conclusion, children (negatively) and obesity/PM2.5 (positively) may be

independently associated with SARS-CoV-2 infection.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

3
Introduction
It has been reported that coexistent chronic diseases are strongly associated with
coronavirus disease 2019 (COVID-19) severity.1

Investigations of predictors for severe

acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection itself, however, have
been seldom performed.

Although meta-regression has been traditionally utilized to

investigate heterogeneity in meta-analysis,2 that considering a nation as a study in metaanalysis may be of use to screen potential risk and protective factors for SARS-CoV-2
infection.

To screen the factors, meta-regression of data from worldwide nations were

herein conducted.

Methods
We extracted 1) total confirmed COVID-19 cases in worldwide 180 nations on May 31,
2020

from

the

"COVID-2019

situation

reports"

(https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)
of the World Health Organization (WHO); 2) national total population (thousands) in
2018, life expectancy at birth (years) in 2016, medical-doctor and nursing/midwiferypersonnel density (/10,000 population) in 2010–2018, hypertension prevalence (%) in
2015, obesity prevalence (%) in 2016, annual particulate matter 2.5 (PM2.5)
concentrations in urban areas (µg/m3) in 2016, population using safely-managed
drinking-water/sanitation services and hand-washing facility with soap/water (%) in 2017,
and daily ambient ultraviolet radiation (J/m2) in 1997–2003 from the "World Health
Statistics 2020: Monitoring health for the Sustainable Development Goals"
(https://www.who.int/gho/publications/world_health_statistics/2020/en/) and "Public
health and environment" (https://apps.who.int/gho/data/node.main.122?lang=en) of the

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

4
WHO; 3) population ages 0-14 and ≥65 (%) in 2018, GDP [Gross Domestic Product] and
GNI [Gross National Income] per capita, PPP [Purchasing Power Parity] (current
international $) in 2016–2018 (mostly 2018), and diabetes prevalence (%) in 2019 from
the World Bank (https://data.worldbank.org/indicator/); 4) inbound tourism (thousands)
in 2014–2018 from the UNWTO [World Tourism Organization of the United Nations]
(https://www.e-unwto.org/doi/abs/10.5555/unwtotfb0000270020142018202001); and 5)
bachelor’s or equivalent (ISCED [International Standard Classification of Education] 6)
(%) in 2016–2018 from the UNESCO [United Nations Educational, Scientific and
Cultural Organization] (http://uis.unesco.org/en/topic/educational-attainment) (Table 1).
Restricted maximum-likelihood meta-regression in the random-effects model was
performed using Comprehensive Meta-Analysis version 3 (Biostat, Englewood, NJ,
USA).

A meta-regression graph depicted the COVID-19 prevalence (%) (plotted as the

logarithm-transformed prevalence on the y-axis) as a function of a given covariate
(plotted on the x-axis).

To adjust for other covariates, we conducted the hierarchical

multivariate models in addition to the univariate model.

Results
Results of the meta-regression were summarized in Table 2.

A slope (coefficient) of

the meta-regression line for the COVID-19 prevalence in the multivariable models was
significantly negative for population ages 0-14 (coefficient, –0.0636; P = .0021; Figure
1A) and positive for obesity prevalence (coefficient, 0.0411; P = .0099; Figure 1B) and
annual PM2.5 concentrations in urban areas (coefficient, 0.0158; P = .0454; Figure 1C),
which would indicate that the COVID-19 prevalence decreases significantly as children

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

5
increase and that the COVID-19 prevalence increases significantly as the obese and
PM2.5 increase.

Discussion
The present meta-regression to screen potential risk and protective factors suggests that
children may be negatively and independently, and obesity/PM2.5 may be positively and
independently associated with SARS-CoV-2 infection.

Our findings could be

strengthened by low case fatality in children with COVID-19 (only one death in a total
of 1124 cases)3 and obesity predicting poor prognosis of COVID-194 demonstrated in
recent systematic reviews.

The present results, however, never denote directly that, for

instance, the obese are at high risk for SARS-CoV-2 infection, which should be noted.
Our findings demonstrate simply that the COVID-19 prevalence is higher in the nation
where the obese are more.

To determine whether, for instance, the obese are at high risk

for SARS-CoV-2 infection, two approaches are considered.

First, potential risk and

protective factors could be investigated in both COVID-19 patients and non-COVID-19
subjects in a community.

It is never facile, however, to investigate the factors in the

non-COVID-19 (healthy) subjects in the community.

Second, the factors could be

examined in both COVID-19 patients and control subjects.

In this occasion, however,

the control subjects, who should be well comparable to the COVID-19 patients, must be
strictly selected.

Meta-regression using "weighted" data from multiple clinical trials

differs from simple regression using individual-patient data from a single study and
accordingly can generate an equation of a "best-fit" regression line to express the relation
between an outcome and a covariate.5

Meta-regression applied in the present study may

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

6
be alternative to the above-mentioned approaches and could be of use at least to screen
the factors.

Conclusion
Children (negatively) and obesity/PM2.5 (positively) may be independently associated
with SARS-CoV-2 infection.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

7
References
1. Liu H, Chen S, Liu M, Nie H, Lu H.

Comorbid Chronic Diseases are Strongly

Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and
Meta-Analysis. Aging Dis. 2020 May 9;11(3):668-678. doi: 10.14336/AD.2020.0502
2. Deeks JJ, Higgins JPT, Altman DG, eds.
meta-analyses.

Chapter 10: Analysing data and undertaking

In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook

for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019.
https://training.cochrane.org/handbook. Accessed June 1, 2020.
3. de Souza TH, Nadal JA, Nogueira RJN, Pereira RM, Brandão MB.
Manifestations of Children with COVID-19: a Systematic Review.

Clinical

Pediatr Pulmonol.

Published online Jun 3, 2020. doi: 10.1002/ppul.24885
4. Tamara A, Tahapary DL.
A

systematic

review.

Obesity as a predictor for a poor prognosis of COVID-19:
Diabetes

Metab

Syndr.

2020;14(4):655-659.

doi:

10.1016/j.dsx.2020.05.020
5. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI; Health Outcomes, Policy,
and Economics (HOPE) Collaborative Group.
analysis: the role of meta-regression.
10.1111/j.1742-1241.2009.02168.x

Understanding heterogeneity in meta-

Int J Clin Pract. 2009;63(10):1426-1434. doi:

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

8
Figure legends
Figure 1. Meta-Regression Lines with their 95% Confidence-Interval Curves Depicting
the COVID-19 Prevalence (Plotted as the Logarithm-Transformed Prevalence on the YAxis) as a Function of a Given Covariate (Plotted on the X-Axis)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

1
Table 1.

Data from Worldwide Nations

Nation

Total
confirmed
cases

Total
population
(thousands)

Cases per Population
Population
100,000
ages 0-14 (%) ages ≥65
population
(%)

GDP per
GNI per capita, Life
capita, PPP
PPP (current
expectancy at
(current
international $) birth (years)
international $)

Medical-doctor
density (/10,000
population)

Nursing/midwiferypersonnel density
(/10,000
population)

Afghanistan
Albania
Algeria
Andorra
Angola
Antigua and
Barbuda

15094
1136
9267
764
84
25

37172
2883
42228
77
30810
96

40.61
39.40
21.95
992.21
0.27
26.04

43
18
30
N/A
47
22

3
14
6
N/A
2
9

2225.8
13835.5
11759.2
N/A
7093.0
21630.2

2240
13820
11370
N/A
6780
20520

62.6
76.4
76.4
N/A
62.6
75.0

2.8
12.2
17.2
33.3
2.1
29.6

1.8
36.5
15.5
40.1
4.1
45.2

Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
(Plurinational
State of)

14702
9282
7185
16638
5246
101
10793
44608
92
41658
58186
18
232
33
8731

44361
2952
24898
8891
9950
386
1569
161377
287
9453
11482
383
11485
754
11353

33.14
314.43
28.86
187.13
52.72
26.17
687.89
27.64
32.06
440.69
506.76
4.70
2.02
4.38
76.90

25
21
19
14
23
22
19
28
17
17
17
30
42
26
31

11
11
16
19
6
7
2
5
16
15
19
5
3
6
7

23300.0
13024.7
51036.4
56871.2
14543.2
36365.3
47297.0
4549.6
16107.0
19345.3
52254.0
7360.0
3237.8
11621.8
8866.4

22470
13190
49440
56720
13780
34370
44700
4760
14140
18650
52590
6650
3200
10580
8640

76.9
74.8
82.9
81.8
73.1
75.7
79.1
72.7
75.6
74.2
81.1
70.5
61.1
70.6
71.5

39.9
44.0
36.8
51.7
34.5
20.1
9.3
5.8
24.8
51.9
30.7
11.2
0.8
4.2
15.9

26.0
61.1
125.5
2.6
64.3
45.7
24.9
4.1
30.6
110.0
194.6
23.4
3.9
18.5
15.6

Bosnia and
Herzegovina

2493

3324

75.00

15

16

14962.0

14920

77.3

21.6

57.3

35
465166
141

2254
209469
429

1.55
222.07
32.87

34
21
23

4
9
5

18059.3
14951.8
61859.9

17460
14530
62820

66.1
75.1
76.4

5.3
21.6
16.1

54.0
101.2
59.0

2513
853
42
421

7052
19751
11175
544

35.64
4.32
0.38
77.39

15
45
46
29

21
2
2
5

22304.9
1904.9
780.1
7068.1

22650
1890
780
6900

74.9
60.3
60.1
73.2

40.3
0.8
1.0
7.8

48.2
8.8
8.5
13.0

Botswana
Brazil
Brunei
Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

2
Cambodia
Cameroon
Canada
Central African
Republic

125
5659
89741
874

16250
25216
37075
4666

0.77
22.44
242.05
18.73

31
43
16
44

5
3
17
3

4261.8
3691.3
49994.1
955.8

3970
3610
49430
1030

69.4
58.1
82.8
53.0

1.9
0.9
23.1
0.7

6.9
0.1
99.4
2.1

Chad
Chile
China
Colombia
Comoros
Congo
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Cyprus
Czechia
Democratic
Republic of the
Congo

759
94858
84570
26688
43
587
1022
2799
2246
2025
943
9230
2965

15478
18729
1435651
49661
832
5244
4999
25069
4156
11338
1189
10666
84068

4.90
506.48
5.89
53.74
5.17
11.19
20.44
11.17
54.04
17.86
79.31
86.54
3.53

47
20
18
23
40
42
21
42
15
16
17
16
46

2
12
11
8
3
3
10
3
20
15
14
19
3

1618.9
24763.0
15376.2
14834.4
3141.5
3357.6
19762.5
3832.1
28115.5
N/A
38513.3
40428.7
1111.7

1590
23750
15320
15320
3160
3000
18670
3660
27700
N/A
39880
38180
1070

54.3
79.5
76.4
75.1
63.9
64.3
79.6
N/A
78.2
79.0
80.7
79.1
60.5

0.4
25.9
19.8
21.8
2.7
1.6
28.9
2.3
30.0
84.2
19.5
41.2
0.7

2.3
133.2
26.6
13.3
6.3
6.3
34.1
6.0
81.2
75.6
52.5
84.0
11.1

Denmark
Djibouti
Dominica
Dominican
Republic

11633
3194
16
16908

5752
959
72
10627

202.24
333.06
22.22
159.10

16
30
N/A
28

20
5
N/A
7

57218.4
5225.0
11814.3
18143.2

57980
5400
10900
17330

81.2
63.8
N/A
73.5

40.1
2.2
11.2
15.3

103.2
7.3
64.4
13.8

Ecuador
Egypt
El Salvador
Equatorial
Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Fiji
Finland
France
Gabon
Gambia

38571
23449
2395
1043

17084
98424
6421
1309

225.77
23.82
37.30
79.68

28
34
27
37

7
5
8
2

11853.7
11643.2
8816.6
20855.8

11530
11350
8320
15750

76.5
70.5
73.7
59.5

20.4
4.5
15.7
4.0

25.1
19.3
18.3
5.0

39
1865
283
1063
18
6826
148436
2613
25

3453
1323
1136
109224
883
5523
64991
2119
2280

1.13
140.97
24.91
0.97
2.04
123.59
228.39
123.31
1.10

N/A
16
38
41
30
16
18
37
44

4
20
4
4
5
22
20
4
3

N/A
36358.0
8815.7
2154.4
14144.4
49549.4
46447.4
15102.5
2196.5

N/A
35340
8820
2140
13180
49720
47490
14110
2160

65.0
77.8
N/A
65.5
69.9
81.4
82.9
66.4
61.9

0.6
44.8
3.3
0.8
8.6
38.1
32.7
6.8
1.0

14.4
111.6
41.4
7.1
33.8
147.4
114.7
29.5
15.4

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

3
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran (Islamic
Republic of)

783
181482
7768
2915
23
4607
3706
1256
150
1584
4886
3867
1806
182143
25773
148950

4003
83124
29767
10522
111
17248
12414
1874
779
11123
9588
9708
337
1352642
267671
81800

19.56
218.33
26.10
27.70
20.72
26.71
29.85
67.02
19.26
14.24
50.96
39.83
535.91
13.47
9.63
182.09

20
14
38
14
24
34
44
42
28
33
32
14
20
27
27
24

15
21
3
22
10
5
3
3
6
5
5
19
15
6
6
6

14594.7
54456.9
5321.0
30357.6
17234.7
8655.4
2555.9
1996.7
9539.0
1810.2
5810.4
31578.8
58058.2
6697.2
11646.5
14535.9

13980
55980
5220
30430
15620
8500
2510
1990
9300
1820
5350
30310
55920
6630
11290
14560

72.6
80.9
63.4
81.1
73.4
73.2
59.8
59.8
66.2
63.5
75.2
76.0
82.4
68.8
69.3
75.7

71.2
42.5
1.4
54.8
14.1
3.5
0.8
1.3
8.0
2.3
3.1
34.1
40.8
8.6
4.3
15.8

47.3
132.4
42.0
36.3
62.8
0.7
1.2
6.9
10.4
6.8
7.4
69.2
162.1
17.3
24.1
4.4

Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kuwait
Kyrgyzstan
Lao People's
Democratic
Republic

6179
24929
17012
232664
575
16851
734
10858
1888
26192
1748
19

38434
4819
8382
60627
2935
127202
9965
18320
51393
4137
6304
7061

16.08
517.31
202.96
383.76
19.59
13.25
7.37
59.27
3.67
633.12
27.73
0.27

38
21
28
13
24
13
34
28
40
22
32
33

3
14
12
23
9
28
4
7
2
3
4
4

10919.9
84459.8
40261.3
42798.1
9975.2
41473.3
10094.0
26172.4
4294.9
51708.3
5245.1
7777.8

10780
68060
40280
43260
9520
43010
10050
22950
4260
59760
5110
7410

69.9
81.5
82.3
82.7
76.0
84.2
74.3
71.1
66.7
74.8
71.4
65.8

7.1
33.1
46.2
39.8
13.1
24.1
23.2
39.8
1.6
26.5
22.1
3.7

20.4
161.0
3.3
57.4
8.1
121.5
28.2
72.9
11.7
74.1
59.4
9.5

Latvia
Lebanon
Lesotho
Liberia
Libya
Lithuania
Luxembourg
Madagascar

1065
1191
2
280
130
1670
4016
758

1928
6859
2108
4819
6679
2801
604
26262

55.24
17.36
0.09
5.81
1.95
59.62
664.90
2.89

16
26
33
41
28
15
16
41

20
7
5
3
4
20
14
3

30744.8
16416.9
3068.2
1533.5
14423.3
35831.9
116786.5
1652.4

30220
16330
3500
1330
14820
34680
74400
1600

75.1
76.3
52.9
62.9
71.9
75.0
82.5
66.1

31.9
21.0
0.7
0.4
20.9
63.5
30.1
1.8

47.5
16.7
32.6
5.3
65.3
98.5
121.7
1.5

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

4
Malawi
Malaysia
Maldives
Mali
Malta
Mauritania
Mauritius
Mexico
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North
Macedonia
Norway
Oman
Pakistan
Panama
Papua New
Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of
Korea
Republic of
Moldova
Romania

279
7762
1672
1250
616
483
335
84627
98
179
324
7780
244
224
23
1401
46257
1154
885
956
9855
2164

18143
31528
516
19078
439
4403
1267
126191
39
3170
628
36029
29496
53708
2448
28096
17060
4743
6466
22443
195875
2083

1.54
24.62
324.03
6.55
140.32
10.97
26.44
67.06
251.28
5.65
51.59
21.59
0.83
0.42
0.94
4.99
271.14
24.33
13.69
4.26
5.03
103.89

44
24
20
48
14
40
18
27
N/A
30
18
27
45
26
37
30
16
20
30
50
44
17

3
7
4
3
20
3
11
7
N/A
4
15
7
3
6
4
6
19
16
5
3
3
14

1071.3
28207.7
18959.4
2344.3
43538.5
3802.9
22752.2
20396.5
12564.9
12203.5
21301.5
8611.7
1321.0
4996.0
10704.7
3330.6
57565.2
42193.8
5833.6
888.8
5281.4
16624.9

1070
27200
17480
2280
40120
3770
24980
19870
N/A
11050
21550
8430
1290
4860
10490
3360
58140
40550
5700
870
5040
15930

64.2
75.3
78.4
58.0
81.4
63.9
74.8
76.6
N/A
69.8
76.8
76.0
60.1
66.8
63.7
70.2
81.6
82.2
75.5
59.8
55.2
N/A

0.4
15.4
45.6
1.3
28.6
1.9
25.3
23.8
75.1
28.6
27.6
7.3
0.8
6.8
4.2
7.5
36.1
35.9
9.8
0.4
3.8
28.7

4.4
34.7
64.3
3.6
94.8
9.3
35.2
24.0
201.6
38.9
52.3
13.9
6.8
10.0
19.5
31.1
111.8
124.5
15.3
2.7
11.8
37.9

8411
10423
69496
12531
8

5338
4829
212228
4177
8606

157.57
215.84
32.75
300.00
0.09

18
22
35
27
36

17
2
4
8
3

67640.2
29289.7
4854.9
31834.0
4336.2

70530
29160
29160
29340
4220

82.5
77.0
66.5
78.0
65.9

29.2
20.0
9.8
15.7
0.7

182.2
42.0
6.7
30.7
4.5

964
148285
17224
23571
32203
55262
11468

6956
31989
106651
37922
10256
2782
51172

13.86
463.55
16.15
62.16
313.99
1986.41
22.41

29
26
31
15
13
14
13

6
8
5
18
22
1
14

13204.3
13093.7
8321.2
31755.8
34272.0
96804.7
39660.9

12830
12450
9980
30410
33520
94910
39630

74.2
75.9
69.3
77.7
81.4
78.1
82.7

13.5
13.0
6.0
23.8
51.2
24.9
23.6

16.6
24.4
49.4
68.9
69.7
72.6
73.0

8098

4052

199.85

16

11

12564.9

13170

71.5

32.1

49.2

19133

19506

98.09

16

18

29061.3

28350

75.2

29.8

73.9

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

5
Russian
Federation

405843

145734

278.48

18

15

28556.3

27840

72.0

37.5

85.4

Rwanda
Saint Kitts and
Nevis

359
15

12302
52

2.92
28.85

40
N/A

3
N/A

2114.1
26530.9

2070
25060

68.0
N/A

1.3
26.8

12.0
42.2

Saint Lucia
Saint Vincent
and the
Grenadines
San Marino
São Tomé and
Príncipe

18
25

182
110

9.89
22.73

19
23

10
10

13960.4
12770.1

13060
12640

75.6
72.0

6.4
6.6

31.5
70.1

687
295

34
211

2020.59
139.81

N/A
43

N/A
3

63037.1
4,040.90

N/A
4060

N/A
68.7

61.1
0.5

82.1
19.2

Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syrian Arab
Republic

83384
3535
11381
11
852
34366
1521
1473
1916
30967
994
239600
1620
4800
12
37113
30762
122

33703
15854
8803
97
7650
5758
5453
2078
15008
57793
10976
46693
21229
41802
576
9972
8526
16945

247.41
22.30
129.29
11.34
11.14
596.84
27.89
70.89
12.77
53.58
9.06
513.14
7.63
11.48
2.08
372.17
360.80
0.72

25
43
16
24
41
12
15
15
47
29
42
15
24
41
27
18
15
31

3
3
18
8
3
11
16
20
3
5
3
19
10
4
7
20
19
5

48756.2
3430.2
17617.0
28243.3
1703.8
98827.4
32616.6
38749.3
N/A
12938.4
N/A
40483.6
13254.7
4767.7
16151.2
53807.9
69366.4
N/A

49200
3330
16710
26920
1580
92150
31960
31960
860
12530
N/A
40570
12900
4430
14390
54640
70140
N/A

74.8
66.8
76.3
73.3
53.1
82.9
77.4
80.9
55.4
63.6
58.6
83.0
75.3
65.1
71.8
82.3
83.3
63.8

26.1
0.7
31.1
21.2
0.3
22.9
34.2
30.9
0.2
9.1
N/A
38.7
10.0
2.6
12.1
39.8
43.0
12.9

54.8
3.1
60.9
80.8
2.2
62.4
3.2
99.7
1.1
13.1
N/A
57.3
21.8
7.0
27.6
118.2
175.4
15.4

Tajikistan
Thailand
The United
Kingdom

3807
3081
272830

9101
69428
67142

41.83
4.44
406.35

37
17
18

3
12
18

3313.5
18481.9
46867.9

3890
17650
46240

70.8
75.5
81.4

21.0
8.1
28.1

47.5
27.6
81.7

24
428
116

1268
7889
1390

1.89
5.43
8.35

38
41
20

4
3
11

3154.9
1590.4
26912.9

4520
1600
26050

68.6
60.6
71.8

7.2
0.8
41.7

16.7
4.1
40.9

1076

11565

9.30

24

8

11009.5

10630

76.0

13.0

25.1

Timor-Leste
Togo
Trinidad and
Tobago
Tunisia

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

6
Turkey
Uganda
Ukraine
United Arab
Emirates

163103
446
23672
33896

82340
42729
44246
9631

198.08
1.04
53.50
351.95

25
47
16
15

8
2
16
1

28139.1
1837.2
9249.5
67549.6

27710
1780
9030
67870

76.4
62.5
72.5
77.2

18.5
1.7
29.9
25.3

27.1
12.4
66.6
57.3

United Republic
of Tanzania

509

56313

0.90

44

3

3240.3

3140

63.9

0.1

5.8

United States of
America

1716078

327096

524.64

19

16

62886.8

63780

78.6

26.1

145.5

Uruguay
Uzbekistan
Venezuela
(Bolivarian
Republic of)

816
3554
1370

3449
32476
28887

23.66
10.94
4.74

21
29
28

15
4
7

22116.8
6898.9
N/A

20590
7110
N/A

77.4
72.3
74.1

50.8
23.7
N/A

19.4
112.8
9.4

Viet Nam
Yemen
Zambia
Zimbabwe

328
314
1057
174

95546
28499
17352
14439

0.34
1.10
6.09
1.21

23
40
45
42

7
3
2
3

7771.2
N/A
3599.0
3360.7

7230
N/A
3500
3350

76.3
65.3
62.3
61.4

8.3
5.3
11.9
2.1

14.5
7.9
13.4
19.3
(continued)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

7
Table 1.

Data from Worldwide Nations (continued)

Nation

Hypertension Obesity
prevalence
prevalence
(%)
(%)

Diabetes
prevalence
(%)

Annual PM2.5
concentrations in
urban areas
(µg/m3)

Daily ambient
ultraviolet
radiation
(J/m2)

Population using
safely-managed
drinking-water
services (%)

Population using
safely-managed
sanitation
services (%)

Population using
hand-washing
facility with
soap/water (%)

Inbound
tourism
(thousands)

Bachelor's or
equivalent
(ISCED 6)
(%)

Afghanistan
Albania
Algeria
Andorra
Angola
Antigua and
Barbuda

30.6
29.0
25.1
18.7
29.7
23.4

5.5
21.7
27.4
25.6
8.2
18.9

9.2
9.0
6.7
7.7
4.5
13.1

59.900
18.200
34.500
11.500
28.400
18.000

4132
2542
3253
2469
5287
5148

N/A
70
N/A
91
N/A
N/A

N/A
40
18
100
N/A
N/A

38
N/A
84
N/A
27
N/A

N/A
5927
2657
8328
N/A
1062

N/A
N/A
N/A
10.2
N/A
N/A

Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
(Plurinational
State of)

22.6
25.5
15.2
21.0
24.5
20.9
21.4
24.7
24.4
27.1
17.5
22.7
27.7
28.1
17.9

28.3
20.2
29.0
20.1
19.9
31.6
29.8
3.6
23.1
24.5
22.1
24.1
9.6
6.4
20.2

5.9
6.1
5.6
6.6
6.1
8.8
15.6
9.2
13.4
5.0
4.6
17.1
1.0
10.3
6.8

11.700
32.900
7.300
13.100
18.500
19.000
69.000
58.600
22.400
19.300
13.000
20.900
30.400
35.400
23.300

3476
2899
3206
1888
2702
4119
4419
4029
5787
1795
1645
4639
5168
4180
5344

N/A
86
N/A
99
74
N/A
99
55
N/A
95
100
N/A
N/A
36
N/A

N/A
48
76
97
N/A
N/A
96
N/A
N/A
81
97
N/A
N/A
N/A
23

N/A
94
N/A
N/A
83
N/A
N/A
35
N/A
N/A
N/A
90
11
N/A
25

10394
N/A
9246
N/A
2850
6622
12045
N/A
1356
11502
N/A
1697
322
N/A
N/A

20.0
24.1
23.3
2.8
15.7
N/A
20.2
5.3
N/A
N/A
19.8
N/A
N/A
7.9
N/A

Bosnia and
Herzegovina

30.8

17.9

9.0

29.700

2205

89

22

N/A

N/A

6.6

Botswana
Brazil
Brunei
Darussalam

29.6
23.3
18.9

18.9
22.1
14.1

5.8
10.4
13.3

20.900
11.800
5.800

4868
4552
5148

N/A
N/A
N/A

N/A
49
N/A

N/A
N/A
N/A

1775
N/A
4521

N/A
15.6
N/A

Bulgaria
Burkina Faso
Burundi
Cabo Verde

28.4
32.6
29.2
29.5

25.0
5.6
5.4
11.8

6.0
7.3
5.1
2.4

20.800
36.300
35.600
31.600

2331
5567
5111
5372

97
N/A
N/A
N/A

64
N/A
N/A
N/A

N/A
12
6
N/A

12368
N/A
N/A
N/A

24.7
N/A
0.9
N/A

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

8
Cambodia
Cameroon
Canada
Central African
Republic

26.1
24.8
13.2
31.2

3.9
11.4
29.4
7.5

6.4
6.0
7.6
6.0

24.900
65.400
6.700
51.200

5152
5185
1887
5498

26
N/A
99
N/A

N/A
N/A
82
N/A

66
9
N/A
N/A

N/A
N/A
31274
N/A

N/A
N/A
18.7
N/A

Chad
Chile
China
Colombia
Comoros
Congo
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Cyprus
Czechia
Democratic
Republic of the
Congo

32.9
20.9
19.2
19.2
27.9
26.2
18.7
27.2
32.4
19.0
19.8
27.9
28.5

6.1
28.0
6.2
22.3
7.8
9.6
25.7
10.3
24.4
24.6
21.8
26.0
6.7

6.0
8.6
9.2
7.4
12.3
6.0
9.1
2.4
5.4
9.6
9.0
7.0
6.0

50.800
23.100
51.000
17.200
18.600
36.400
16.700
23.900
17.600
21.600
17.100
15.600
37.400

5669
3982
2908
5385
5524
4943
4884
4931
1976
4401
3439
1707
5100

N/A
99
N/A
73
N/A
45
94
37
90
N/A
100
98
N/A

N/A
77
72
17
N/A
N/A
N/A
N/A
58
44
75
94
N/A

6
N/A
N/A
65
N/A
48
N/A
19
N/A
85
N/A
N/A
4

N/A
6603
158606
4282
N/A
158
3300
1965
57668
4712
4024
34701
N/A

N/A
13.1
N/A
8.2
N/A
N/A
18.4
N/A
N/A
N/A
16.4
4.6
3.3

Denmark
Djibouti
Dominica
Dominican
Republic

20.6
26.8
22.5
21.5

19.7
13.5
27.9
27.6

8.3
5.1
11.6
8.6

10.300
41.000
18.800
13.300

1691
5461
5464
4880

97
N/A
N/A
N/A

95
36
N/A
N/A

N/A
N/A
N/A
55

30801
N/A
198
7576

19.0
N/A
N/A
16.9

Ecuador
Egypt
El Salvador
Equatorial
Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Fiji
Finland
France
Gabon
Gambia

17.9
25.0
18.7
28.4

19.9
32.0
24.6
8.0

5.5
17.2
8.8
6.0

15.500
79.600
23.800
49.100

4929
4202
5364
4635

75
N/A
N/A
N/A

42
61
N/A
N/A

81
90
91
N/A

2535
11346
2536
N/A

10.9
5.5
6.7
N/A

29.1
27.4
29.8
30.3
21.7
19.4
22.0
25.5
29.1

5.0
21.2
16.5
4.5
30.2
22.2
21.6
15.0
10.3

5.1
4.2
4.5
4.3
14.7
5.6
4.8
6.0
1.9

41.100
7.000
16.200
34.000
10.500
6.500
12.400
37.800
32.300

5914
1781
3900
5929
4431
1494
1907
4654
5358

N/A
93
N/A
11
N/A
100
98
N/A
N/A

N/A
97
N/A
N/A
N/A
100
88
N/A
N/A

N/A
N/A
24
8
N/A
N/A
N/A
N/A
8

142
6071
1277
N/A
1058
N/A
211998
N/A
N/A

N/A
3.3
N/A
N/A
3.7
12.4
8.5
N/A
N/A

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

9
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran (Islamic
Republic of)

26.3
19.9
23.7
19.1
24.3
21.2
30.3
30.3
23.1
24.5
21.4
30.0
19.7
25.8
23.8
19.7

21.7
22.3
10.9
24.9
21.3
21.2
7.7
9.5
20.2
22.7
21.4
26.4
21.9
3.9
6.9
25.8

5.8
10.4
2.5
4.7
10.7
10.0
2.4
2.4
11.6
6.7
7.3
6.9
5.8
10.4
6.3
9.6

24.000
11.900
31.100
16.400
21.800
24.200
22.200
26.500
21.600
14.700
21.500
16.300
5.900
68.000
16.400
34.400

2489
1812
5166
2753
4875
5141
5391
5319
5203
5016
4924
1932
957
4514
5220
4038

80
100
36
100
87
56
N/A
N/A
N/A
N/A
N/A
90
100
N/A
N/A
92

27
97
N/A
90
N/A
N/A
N/A
N/A
N/A
N/A
N/A
96
82
N/A
N/A
N/A

N/A
N/A
41
N/A
N/A
77
17
6
77
23
N/A
N/A
N/A
60
64
N/A

7203
N/A
N/A
33072
528
2406
N/A
N/A
N/A
1333
2303
57667
2488
N/A
15810
7295

6.9
13.9
N/A
17.7
N/A
N/A
N/A
N/A
N/A
N/A
9.5
11.8
N/A
N/A
8.8
13.7

Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kuwait
Kyrgyzstan
Lao People's
Democratic
Republic

25.2
19.7
16.6
21.2
21.8
17.6
21.0
27.1
26.7
23.6
26.7
24.8

30.4
25.3
26.1
19.9
24.7
4.3
35.5
21.0
7.1
37.9
16.6
5.3

8.8
3.2
9.7
5.0
11.3
5.6
12.7
6.1
3.1
12.2
6.1
6.4

60.100
8.700
19.400
15.700
13.600
11.800
31.700
14.500
25.800
58.900
17.400
25.500

3825
1509
3682
2444
4942
2521
4026
2257
5803
4214
3094
4735

59
97
100
95
N/A
98
94
90
N/A
100
68
16

41
82
94
96
N/A
99
81
N/A
N/A
100
N/A
58

95
N/A
N/A
N/A
N/A
N/A
N/A
99
25
N/A
89
50

N/A
N/A
4389
93228.6
4319
31192
4922
8789
1449
8508
6947
4186

N/A
18.6
N/A
N/A
N/A
N/A
N/A
34.0
N/A
9.8
N/A
N/A

Latvia
Lebanon
Lesotho
Liberia
Libya
Lithuania
Luxembourg
Madagascar

29.4
20.7
29.0
28.3
23.7
29.3
21.9
28.1

23.6
32.0
16.6
9.9
32.5
26.3
22.6
5.3

5.0
11.2
4.5
2.4
10.2
3.8
5.0
4.5

14.400
30.700
28.100
17.000
41.700
12.300
10.400
22.500

1671
2953
4439
4926
3861
1801
1687
4771

95
48
N/A
N/A
N/A
92
100
N/A

86
22
N/A
N/A
26
91
97
N/A

N/A
N/A
2
1
N/A
N/A
N/A
N/A

7775
N/A
1173
N/A
N/A
6115
N/A
N/A

15.4
N/A
N/A
N/A
N/A
21.2
N/A
N/A

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

10
Malawi
Malaysia
Maldives
Mali
Malta
Mauritania
Mauritius
Mexico
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North
Macedonia
Norway
Oman
Pakistan
Panama
Papua New
Guinea

28.9
22.9
24.4
32.6
19.4
31.7
25.0
19.7
N/A
29.0
29.1
26.1
29.1
24.6
28.5
29.4
18.7
16.2
20.8
33.4
23.9
28.5

5.8
15.6
8.6
8.6
28.9
12.7
10.8
28.9
N/A
20.6
23.3
26.1
7.2
5.8
17.2
4.1
20.4
30.8
23.7
5.5
8.9
22.4

4.5
16.7
9.2
2.4
8.3
7.1
22.0
13.5
2.9
4.7
9.0
7.0
3.3
3.9
4.5
7.2
5.4
6.2
11.4
2.4
3.1
9.3

21.900
17.300
7.700
29.000
14.000
41.700
13.500
20.900
12.200
49.500
19.300
31.100
18.400
34.600
21.000
99.500
12.100
5.800
19.000
73.000
46.300
33.000

5019
5225
10224
5617
3091
5547
5055
4974
1907
2226
N/A
3568
4646
4565
5305
4130
1662
2487
5078
5811
5251
N/A

N/A
93
N/A
N/A
100
N/A
N/A
43
100
24
94
70
N/A
N/A
N/A
27
100
100
52
N/A
20
81

N/A
89
N/A
N/A
93
N/A
N/A
50
100
N/A
N/A
39
N/A
N/A
N/A
N/A
97
89
N/A
10
27
17

9
N/A
96
52
N/A
43
N/A
88
N/A
71
N/A
N/A
N/A
79
45
48
N/A
N/A
N/A
N/A
42
N/A

N/A
N/A
N/A
N/A
3232
1002
1431
96497
N/A
598
N/A
12489
2870
N/A
1581
N/A
N/A
3858
1412
N/A
5265
N/A

N/A
9.7
N/A
2.1
11.8
N/A
7.6
14.5
N/A
N/A
N/A
N/A
1.6
N/A
N/A
N/A
19.1
22.5
N/A
N/A
N/A
N/A

19.7
24.8
30.5
19.9
25.6

23.1
27.0
8.6
22.7
21.3

5.3
10.1
19.9
7.7
17.9

7.800
36.200
56.200
12.000
11.500

1439
5102
4227
4898
5377

98
90
35
v
N/A

76
N/A
N/A
N/A
N/A

N/A
97
60
N/A
N/A

N/A
3242
N/A
2487
195

16.4
N/A
6.8
N/A
N/A

Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of
Korea
Republic of
Moldova

24.6
13.7
22.6
28.7
24.4
22.4
11.0

20.3
19.7
6.4
23.1
20.8
35.1
4.7

9.6
6.6
7.1
6.1
9.8
15.6
6.9

11.700
29.000
18.700
21.500
8.100
91.700
24.700

4038
5906
4928
1749
2585
4905
2535

64
50
47
100
95
96
98

58
43
52
93
85
96
100

80
N/A
78
N/A
N/A
N/A
N/A

4183
5384
N/A
85946
N/A
N/A
15347

6.1
10.0
15.6
5.7
5.0
17.6
N/A

29.8

18.9

5.7

16.500

1910

73

N/A

N/A

N/A

19.0

Romania

30.0

22.5

6.9

15.400

2403

82

77

N/A

11720

N/A

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

11
Russian
Federation

27.2

23.1

6.1

14.700

2071

76

61

N/A

24551

N/A

Rwanda
Saint Kitts and
Nevis

26.7
25.3

5.8
22.9

5.1
13.3

40.700
12.300

1795
5130

N/A
N/A

N/A
N/A

5
N/A

1307
1278

3.8
N/A

Saint Lucia
Saint Vincent
and the
Grenadines
San Marino
São Tomé and
Príncipe

27.1
23.3

19.7
23.7

11.6
11.6

21.200
21.400

5009
5164

N/A
N/A

N/A
N/A

N/A
N/A

1165
356

N/A
N/A

N/A
25.8

N/A
12.4

5.9
2.4

13.400
25.200

4966
1932

100
N/A

77
N/A

N/A
41

1874
N/A

4.3
N/A

Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syrian Arab
Republic

23.3
30.2
29.5
23.5
30.3
14.6
28.5
30.5
32.9
26.9
N/A
19.2
22.4
N/A
22.4
19.3
18.0
24.5

35.4
8.8
21.5
14.0
8.7
6.1
20.5
20.2
8.3
28.3
N/A
23.8
5.2
N/A
26.4
20.6
19.5
27.8

15.8
2.4
9.0
12.3
2.4
2.4
6.5
5.9
5.1
12.7
10.2
6.9
10.7
22.1
12.5
4.8
5.7
13.5

86.700
39.700
24.700
18.600
20.600
18.300
18.000
16.400
28.000
24.300
40.900
9.800
15.100
46.800
25.800
6.100
10.400
37.400

4422
5384
N/A
5356
5570
5087
3979
1795
4071
5773
4111
2705
5264
5783
4799
1587
2158
3501

N/A
N/A
75
N/A
10
100
100
98
N/A
N/A
N/A
98
N/A
N/A
N/A
100
95
N/A

78
21
25
N/A
13
100
83
83
N/A
N/A
N/A
97
N/A
N/A
N/A
93
100
N/A

N/A
24
N/A
N/A
19
N/A
N/A
N/A
10
44
N/A
N/A
N/A
23
N/A
N/A
N/A
71

17570
1376
N/A
405
66
18508
23092
N/A
N/A
15004
N/A
124060
2521
3093
279
N/A
N/A
N/A

23.5
1.2
12.7
N/A
N/A
31.6
2.1
5.4
N/A
6.8
N/A
9.0
3.6
N/A
N/A
12.4
18.8
N/A

Tajikistan
Thailand
The United
Kingdom

26.1
22.3
15.2

14.2
10.0
27.8

6.1
7.0
3.9

42.800
26.600
10.600

3538
4862
1576

48
N/A
100

N/A
N/A
98

73
84
N/A

1035
N/A
37905

0.9
12.8
17.2

Timor-Leste
Togo
Trinidad and
Tobago

27.6
28.9
25.8

3.8
8.4
18.6

6.7
2.4
11.0

18.200
31.200
22.400

5637
5307
5245

N/A
N/A
N/A

N/A
N/A
N/A

28
10
N/A

N/A
N/A
501

N/A
N/A
N/A

Tunisia

23.2

26.9

8.5

35.700

3262

93

78

79

N/A

15.2

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

12
Turkey
Uganda
Ukraine
United Arab
Emirates

20.3
27.3
27.1
21.1

32.1
5.3
24.1
31.7

11.1
2.5
6.1
16.3

41.200
48.700
19.400
37.200

2924
5499
1843
4862

N/A
7
92
N/A

65
N/A
68
96

N/A
21
N/A
N/A

46113
N/A
14342
N/A

16.7
N/A
N/A
37.2

United Republic
of Tanzania

27.3

8.4

5.7

25.100

5483

N/A

25

48

1506

N/A

United States of
America

12.9

36.2

10.8

7.600

2736

100

90

N/A

169324.918

21.9

Uruguay
Uzbekistan
Venezuela
(Bolivarian
Republic of)

20.7
25.6
18.6

27.9
16.6
25.6

7.3
6.5
7.0

8.700
28.900
16.800

3235
3172
5211

N/A
59
N/A

N/A
N/A
24

N/A
N/A
N/A

3954
5346
429

9.4
16.3
24.1

Viet Nam
Yemen
Zambia
Zimbabwe

23.4
30.7
27.1
28.2

2.1
17.1
8.1
15.5

6.0
5.4
4.5
1.8

30.100
44.300
23.800
19.100

4293
6089
5265
4918

N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A

86
50
14
37

15498
N/A
N/A
2580

N/A
N/A
N/A
2.6

Abbreviation: GDP, Gross Domestic Product; GNI, Gross National Income; ISCED, International Standard Classification of Education; PM2.5, particulate matter 2.5; PPP, Purchasing Power
Parity.

Table 2. Meta-regression Summary
Model, covariate

Lower limit
Coefficient of 95 % CI

Univariable model I
Age distribution
[1] Population ages 0-14 (%)
–0.1136
[2] Population ages ≥65 (%)
0.1521
Economy
[3] GDP per capita, PPP (current international $)
0.0001
[4] GNI per capita, PPP (current international $)
0.0001
Multivariable model I including all the above-mentioned covariates [1]–[4]
[1] Population ages 0-14 (%)
–0.0636
[2] Population ages ≥65 (%)
–0.0163
[3] GDP per capita, PPP (current international $)
0.0000
[4] GNI per capita, PPP (current international $)
0.0000

Upper limit P value
of 95 % CI

–0.1360
0.1114

–0.0913
0.1928

<0.0001*
<0.0001*

0.0000
0.0001

0.0001
0.0001

<0.0001*
<0.0001*

–0.1038
–0.0738
–0.0000
–0.0000

–0.0234
0.0411
0.0001
0.0001

Figure

0.0021* Figure 1A
0.5750
0.8818
0.1768

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
Multivariable
model
II-1
for
[1]–[4]
(which was
not certified by peer
review)
is theadjusting
author/funder,
whocovariates
has granted medRxiv
a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Public health
[5] Life expectancy at birth (years)
[6] Medical-doctor density (/10,000 population)
[7] Nursing/midwifery-personnel density
(/10,000 population)

0.0300
0.0292
0.0047

–0.0385
0.0056
–0.0035

0.0984
0.0529
0.0130

0.3885
0.0156*
0.2604

Multivariable model II-2 adjusting for covariates [1]–[4] and [8]–[10]
[5] Life expectancy at birth (years)
0.0133
[6] Medical-doctor density (/10,000 population)
0.0158
[7] Nursing/midwifery-personnel density
0.0022
(/10,000 population)

–0.0654
–0.0085
–0.0058

0.0919
0.0402
0.0103

0.7396
0.2015
0.5844

–0.0086
0.0411
–0.0261

–0.0790
0.0100
–0.0935

0.0619
0.0722
0.0413

0.8107
0.0099* Figure 1B
0.4454

0.0158

0.0003

0.0313

0.0454* Figure 1C

0.0001

–0.0002

0.0003

0.6534

0.0171

–0.0044

0.0386

0.1180

[14] Population using safely-managed sanitation
services (%)

–0.0030

–0.0222

0.0161

0.7521

[15] Population using hand-washing facility with
soap/water (%)

–0.0170

–0.0406

0.0065

0.1525

Multivariable model III adjusting for covariates [1]–[7]
Disease
[8] Hypertension prevalence (%)
[9] Obesity prevalence (%)
[10] Diabetes prevalence (%)
Multivariable model IV adjusting for covariates [1]–[10]
Environment
[11] Annual PM2.5 concentrations in urban areas
(µg/m3)
[12] Daily ambient ultraviolet radiation (J/m2)
Multivariable model V adjusting for covariates [1]–[12]
Health infrastructure
[13] Population using safely-managed drinkingwater services (%)

Miscellaneous
[16] Inbound tourism (millions)
0.0027
–0.0056
0.0110
0.5243
[17] Bachelor's or equivalent (ISCED 6) (%)
–0.0029
–0.0485
0.0427
0.9004
Abbreviation: CI, confidence interval; GDP, Gross Domestic Product; GNI, Gross National Income; ISCED, International Standard
Classification of Education; PM2.5, particulate matter 2.5; PPP, Purchasing Power Parity.
*Statistically significant.

A

-1.00

Log COVID-19 prevalence (%)

-2.00

-3.00

-4.00

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
-5.00

-6.00

-7.00
0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

40.0

45.0

50.0

55.0

60.0

30.0

35.0

40.0

45.0

50.0

Population ages 0-14 (%)

B

-1.00

-1.50

Log COVID-19 prevalence (%)

-2.00

-2.50

-3.00

-3.50

-4.00

-4.50

-5.00

-5.50

-6.00
-10.0

-5.0

0.0

5.0

10.0

15.0

20.0

25.0

Obesity prevalence (%)

C

1.00

Log COVID-19 prevalence (%)

0.00

-1.00

-2.00

medRxiv preprint doi: https://doi.org/10.1101/2020.06.06.20124016; this version posted June 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All-3.00
rights reserved. No reuse allowed without permission.

-4.00

-5.00

-6.00
-20.0

0.0

20.0

40.0

60.0

80.0

Annual PM2.5 concentrations in urban areas (micrograms/m^3)

100.0

120.0

